Scarica l'app Stockscreener
6.39
3.40%
0.21
Precedente Chiudi:
$6.18
Aprire:
$6.2
Volume 24 ore:
93,990
Relative Volume:
0.21
Capitalizzazione di mercato:
$424.03M
Reddito:
$555.06M
Utile/perdita netta:
$-39.48M
Rapporto P/E:
-10.65
EPS:
-0.6
Flusso di cassa netto:
$29.05M
1 W Prestazione:
-2.14%
1M Prestazione:
-8.97%
6M Prestazione:
-41.86%
1 anno Prestazione:
-3.91%
Intervallo 1D:
$6.20
$6.47
Intervallo di 1 settimana:
$6.03
$6.91
Portata 52W:
$6.02
$14.38
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Confronta BVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.39 | 410.09M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
129.24 | 221.54B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.45 | 156.19B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
381.28 | 144.43B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.51 | 114.47B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.67 | 46.53B | 5.69B | 4.15B | 623.10M | 6.95 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
Bioventus Secures $400 Million Credit Agreement - TipRanks
Bioventus Enters into a New $400 Million Senior Secured - GlobeNewswire
Bioventus Lands $400M Credit Deal: Saves $2M Annually with 75 BPS Rate Cut - Stock Titan
What is Bioventus Inc. company’s growth strategyExceptional market positioning - jammulinksnews.com
What are analysts’ price targets for Bioventus Inc. in the next 12 monthsExponential wealth increase - jammulinksnews.com
How does Bioventus Inc. compare to its industry peersInvest confidently with advanced analysis tools - jammulinksnews.com
How volatile is Bioventus Inc. stock compared to the marketBuild wealth faster with consistent growth stocks - jammulinksnews.com
Bioventus gets FDA nod for pain management devices - MSN
What institutional investors are buying Bioventus Inc. stockHigh-yield investments - jammulinksnews.com
How strong is Bioventus Inc. company’s balance sheetAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
How does Bioventus Inc. generate profit in a changing economyUnlock expert insights for smarter investing - jammulinksnews.com
What are Bioventus Inc. company’s key revenue driversIdentify winners with top-tier analysis - jammulinksnews.com
Is Bioventus Inc. stock overvalued or undervaluedGet daily expert analysis for smarter investing - jammulinksnews.com
Should I hold or sell Bioventus Inc. stock in 2025Breakthrough capital growth - jammulinksnews.com
What analysts say about Bioventus Inc. stockUnmatched market gains - jammulinksnews.com
What catalysts could drive Bioventus Inc. stock higher in 2025Invest confidently with expert support - jammulinksnews.com
Is it the right time to buy Bioventus Inc. stockInvest smarter with real-time trading signals - jammulinksnews.com
Is Bioventus Inc. a growth stock or a value stockMaximize returns with strategic stock selection - jammulinksnews.com
What are the latest earnings results for Bioventus Inc.Robust financial gains - jammulinksnews.com
Market reaction to Bioventus Inc.’s recent newsSmart Safety Strategy With Real Data Analysis - Newser
Understanding Bioventus Inc.’s price movementLow Risk Stock Trade Opportunity Analysis - Newser
Competitive Positioning of Bioventus Inc.: Is It Leading or LaggingFree Daily Smart Money Movement Monitor - Newser
The FDA Grants 510(k) Clearances For Bioventus' Talismann And Stimtrial, Expanding The Company's Portfolio Of Peripheral Nerve Stimulation Solutions For Chronic Pain Management - 富途牛牛
Bioventus Gains FDA Clearance for Key PNS Products - TipRanks
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Top chart patterns to watch in Bioventus Inc.Buy Alert Based on RSI and Volume - Newser
Price action breakdown for Bioventus Inc.Yield Curve Outlook and Long-Term Implication Summary - Newser
What’s next for Bioventus Inc. stock priceAI Trend Detection for Entry Timing - Newser
Can Bioventus Inc. recover in the next quarterGrowth Watchlist for Long Term Positioning - Newser
How Bioventus Inc. stock performs during market volatilityCapital Growth With Controlled Risk Picks Suggested - beatles.ru
Bioventus receives FDA clearance for two pain management devices - Investing.com
Bioventus receives FDA clearance for two pain management devices By Investing.com - Investing.com UK
Bioventus gets FDA nod for pain management devices (BVS) - Seeking Alpha
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products - The Manila Times
Bioventus receives FDA clearance for TalisMann and StimTrial PNS solutions. - AInvest
Bioventus Secures Dual FDA Clearance for Revolutionary Non-Opioid Pain Management Technology - Stock Titan
What makes Bioventus Inc. stock price move sharplySector-Wise Stock Strength Trend Analysis - Newser
Momentum divergence signals in Bioventus Inc. chartFree Reliable Chart-Based Trade Entries - Newser
New Product Launches: Will They Boost Bioventus Inc. Stock in 2025Breakout Monitoring with Momentum Analysis - Newser
What indicators show strength in Bioventus Inc.Stock Entry Points Based on Technicals - Newser
Bioventus Inc. Recovery Gathers Momentum on Chart SignalsRisk Adjusted Technical Entry Plan Gains Followers - metal.it
What candlestick patterns are forming on Bioventus Inc.Free Swing Setup With Technical Confirmation - Newser
What to do if you’re stuck in Bioventus Inc.Free Conservative Entry for High Return Setup - Newser
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 - The Manila Times
Medical Innovation Leader Bioventus Announces Q2 2025 Earnings Date: Key Details for Investors - Stock Titan
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.06%
2.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):